The XE120-L platform is an innovation from the newly formed labs of Elarex Inc. During the course of the pandemic, it has become clear that mRNA-LNP vaccines represent a new frontier of genomic medicine but are limited by their extreme dependence on the cold chain. Our XE120-L platform enables the stabilization of mRNA-LNPs in liquid, without specialized lipids or mRNA.

The excipients used in the technology are all approved for parenteral administration by the U.S. FDA, and the process to create the LNPs is straightforward and simple.

This dried technology platform is a straightforward, patented formulation that has been developed over the past five years at McMaster University. It offers exceptional temperature stabilization that has been shown to stabilize vaccines that normally require -80°C storage to be stored at 40°C, a difference of 120 degrees. In vivo data in mice has shown that this stabilization results in effective vaccines when stored at the higher temperature. No freeze drying is necessary, and the process is simple, with all the components of the solution on the FDA “GRAS” list (Generally Regarded as Safe). This differs from all the other competitors’ offerings in this field.
This technology has also been shown to be applicable to a wide array of bio-therapeutics beyond vaccines. Small molecules, enzymes, biologics, DNA and RNA have all been shown to benefit from the stabilization offered by this technology.